These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12384541)

  • 1. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B; Le T
    Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H; Fox JA; Totpal K; Aikawa M; Dupree K; Sinicropi D; Lowe J; Escandón E
    Oncogene; 2002 May; 21(22):3611-9. PubMed ID: 12032863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
    Shimoyama S; Mochizuki Y; Kusada O; Kaminishi M
    Int J Oncol; 2002 Sep; 21(3):643-8. PubMed ID: 12168112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
    Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
    Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
    van Geelen CM; de Vries EG; Le TK; van Weeghel RP; de Jong S
    Br J Cancer; 2003 Jul; 89(2):363-73. PubMed ID: 12865931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
    Wang S; El-Deiry WS
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
    Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
    Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
    Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
    Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
    Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
    Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells.
    Kim YH; Park JW; Lee JY; Kwon TK
    Carcinogenesis; 2004 Oct; 25(10):1813-20. PubMed ID: 15142888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.